Cancer survival in Cali, Colombia: A population-based study, 1995-2004
Article Sidebar
Main Article Content
Background: There is limited information on population-based cancer survival data in Latin America.
Objetive: To obtain estimates of survival for some cancers recognized as a public health priority in Colombia using data from the Cancer Registry of Cali for 1995-2004.
Methods: All cancer cases for residents of Cali were included for the following sites: breast (3,984), cervix uteri (2,469), prostate (3,999), stomach (3,442) and lung (2,170). Five-year relative survival estimates were calculated using the approach described by Estève.
Results: Five-year relative survival was 79% in patients with prostate cancer and 68% and 60% in women with breast or cervix uteri cancer, respectively. The cure fraction was 6% in subjects with lung cancer and 15% in those with stomach cancer. The probability of dying from breast or prostate cancer in people in the lower socio-economic strata (SES) was 1.8 and 2.6 times greater, respectively, when compared to upper SES, p <0.001. Excess mortality associated with cancer was independent of age in prostate or breast cancer. After adjusting for age, sex and SES, the risk of dying from breast, cervix uteri, prostate and lung cancer during the 2000-2004 period decreased 19%, 13%, 48% and 16%, respectively, when compared with the period of 1995-1999. There was no change in the prognosis for patients with stomach cancer.
Conclusions: Survival for some kinds of cancer improved through the 1995-2004 period, however health care programs for cancer patients in Cali are inequitable. People from lower SES are the most vulnerable and the least likely to survive.
Gloeckler RL, Hankey B, Harras A, Devesa S. Cancer incidence, mortality, and patient survival in the United States. In: Schottenfeld D, Fraumeni FJ. Cancer epidemiology and prevention, 2nd ed., vol. 2. New York: Oxford University Press, 1996: 168–91.
Berrino F, Gatta G, Sant M, Capocaccia R. The EUROCARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. Eur J Cancer. 2001; 37: 673–7.
Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001; 37: 1659–67.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8: 784–96.
Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol. 2008; 9: 730–56.
Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010; 11: 165–73.
Coleman MP. Cancer survival in the developing world. Lancet Oncol. 2010; 11: 110–1.
Berrino F, Estève J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995; (132): 1–14.
Coebergh JW, Sant M, Berrino F, Verdecchia A. Survival of adult cancer patients in Europe diagnosed from 1978-1989 the Eurocare II study. Europ J Cancer. 1998; 34: 2137–278.
Bravo LE, Collazos T, Collazos P, García LS, Correa P. Trends of Cancer Incidence and Mortality in Cali, Colombia. 50 years experience. Colomb Med (Cali) 2012; 43(4): 246-25.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 1079–92.
Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents.Vol. IX. Lyon: IARC Press; 2007.
Doll R, Muir C, Waterhouse J. Cancer Incidence in Five Continents.Vol. II. New York: Springer-Verlag Berlin - Heidelberg; 1970.
Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer Incidence in Five Continents.Vol. V. Lyon: IARC Press; 1987.
Parkin D, Muir C, Whelan S, Gao Y, Ferlay J, Powell J. Cancer Incidence in Five Continents.Vol. VI. Lyon: IARC Press; 1992.
Parkin D, Whelan S, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents.Vol. VII. Lyon: IARC Press; 1997.
Parkin D, Whelan S, Ferlay J, Teppo L, Thomas D. Cancer Incidence in Five Continents.Vol. VIIIed. Lyon: IARC Press; 2002.
Waterhouse J, Muir C, Shanmugaratnam K, Powell J. Cancer Incidence in Five Continents.Vol. IVed., vol. 42. Lyon: IARC Press; 1982.
Waterhouse J, Muir C, Correa P, Powell J. Cancer Incidence in Five Continents. III .ed. vol. 15. IARC Press; 1984.
EZU Enterprise. Geografic business intelligence solutions (Geobis International) 9.0.
Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. National Cancer Institute Monograph. 1961; 6: 101–21.
Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982; 38: 933–42.
Surveillance Research Program NCI . SEER*Stat software, ed.Version. MD: National Cancer Institute; 2012.
Estève J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990; 9: 529–38.
Gamel JW, Weller EA, Wesley MN, Feuer EJ. Parametric cure models of relative and cause-specific survival for grouped survival times. Comput Methods Programs Biomed. 2000; 61: 99–110.
CanSurv Statistical Methodology and Applications Branch.Data Modeling Branch.National Cancer Institute.ed . Version 1.1. Bethesda: MD; 2012.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125–132.
Aristizabal N, Cuello C, Correa P, Collazos T, Haenszel W. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J Cancer. 1984; 34: 5–9.
Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006; 12(1): S54–S69.
Charry LC, Carrasquilla G, Roca S. Equity regarding early breast cancer screening according to health insurance status in Colombia. Rev Salud Publica. 2008; 10: 571–82.
Tsai TC. Second chance for health reform in Colombia. Lancet. 2010; 375: 109–10.
Yamin AE. Colombia’s health reform: false debates, real imperatives. Lancet. 2010; 375: 803.
Downloads
- Rodrigo Guerrero, Luis Eduardo Bravo, Edgar Muñoz, Elvia Karina Grillo Ardila, Esteban Guerrero, COVID-19: The Ivermectin African Enigma , Colombia Medica: Vol. 51 No. 4 (2020): Damage Control Surgery (I)
- Luis Eduardo Bravo, Armando Cortés, Edwin Carrascal, Roberto Jaramillo, Luz Stella García, Paco Eduardo Bravo, Aníbal Badel, Pablo Andrés Bravo, Helicobacter pylori: patología y prevalencia en biopsias gástricas en Colombia. , Colombia Medica: Vol. 34 No. 3 (2003)
- Luis Eduardo Bravo Ocaña, Paola Collazos, Elvia Karina Grillo Ardila, Luz Stella García, Erquinovaldo Millán, Patricia Mera, Jorge Holguín, Mortality from respiratory infections and chronic non-communicable diseases before the COVID-19 pandemic in Cali, Colombia. , Colombia Medica: Vol. 51 No. 2 (2020): Coronavirus disease 2019
- Luis Eduardo Bravo, Nubia Muñoz, Epidemiology of cancer in Colombia , Colombia Medica: Vol. 49 No. 1 (2018): Colombia Cancer Epidemiology
- Luis Eduardo Bravo, Luz Stella García, Paola Collazos, Edwin Carrascal, Oscar Ramírez, Armando Cortés, Marcela Nuñez, Erquinovaldo Millán, Reliable information for cancer control in Cali, Colombia , Colombia Medica: Vol. 49 No. 1 (2018): Colombia Cancer Epidemiology
- Luz Stella Garcia, Luis Eduardo Bravo, Paola Collazos, Oscar Ramirez, Edwin Carrascal, Marcela Nuñez, Nelson Portilla, Erquinovaldo Millan, Cali Cancer Registry Methods , Colombia Medica: Vol. 49 No. 1 (2018): Colombia Cancer Epidemiology
- Armando Cortés, Lina María Isaza, Luis Eduardo Bravo, María Fernanda Palomino, Incidencia de seroconversión para infecciones virales trasmisibles por transfusión en donantes habituales de sangre en Cali. , Colombia Medica: Vol. 32 No. 4 (2001)
- Luis Eduardo Bravo, Luz Stella Garcia, Paola Collazos, Edwin Carrascal, Elvia Karina Grillo-Ardila, Erquinovaldo Millan, Jorge Holguín, Cancer epidemiology in Cali, 60 years of experience , Colombia Medica: Vol. 53 No. 1 (2022): Cancer incidence and mortality
- Rodrigo Guerrero, Luis Eduardo Bravo, Edgar Muñoz, Elvia Karina Grillo Ardila, Esteban Guerrero, Reply to a letter from Robert Colebunders entitled COVID-19: The African Enigma , Colombia Medica: Vol. 52 No. 2 (2021): Damage Control Surgery (II)
- Luis Eduardo Bravo, Luz Stella Garcia, Paola Collazos, Jorge Alirio Holguin, Isabelle Soerjomataram, Adalberto Miranda-Filho, Trends in long-term cancer survival in Cali, Colombia: 1998-2017 , Colombia Medica: Vol. 53 No. 1 (2022): Cancer incidence and mortality
Accepted 2014-09-17
Published 2014-09-30
Similar Articles
- Maria Clara Yepez, Luis Eduardo Bravo, Arsenio Hidalgo Troya, Daniel Marcelo Jurado, Luisa Mercedes Bravo, Cancer incidence and mortality in the municipality of Pasto, 1998 – 2007 , Colombia Medica: Vol. 43 No. 4 (2012): Numbers in cancer: 50-year of The Population-based Cancer Registry of Cali
- Luis Eduardo Bravo, Luz Stella Garcia, Paola Collazos, Jorge Alirio Holguin, Isabelle Soerjomataram, Adalberto Miranda-Filho, Trends in long-term cancer survival in Cali, Colombia: 1998-2017 , Colombia Medica: Vol. 53 No. 1 (2022): Cancer incidence and mortality
You may also start an advanced similarity search for this article.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use